Jazz Pharmaceuticals Current Valuation vs. Price To Book
| J7Z Stock | EUR 116.85 1.15 0.97% |
For Jazz Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Jazz Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Jazz Pharmaceuticals plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Jazz Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Jazz Pharmaceuticals plc over time as well as its relative position and ranking within its peers.
Jazz |
Jazz Pharmaceuticals plc Price To Book vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Jazz Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Jazz Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Jazz Pharmaceuticals plc is rated below average in current valuation category among its peers. It is rated fifth overall in price to book category among its peers . The ratio of Current Valuation to Price To Book for Jazz Pharmaceuticals plc is about 3,932,835,237 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Jazz Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Jazz Current Valuation vs. Competition
Jazz Pharmaceuticals plc is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 683.64 Billion. Jazz Pharmaceuticals holds roughly 13.72 Billion in current valuation claiming about 2.01% of stocks in Biotechnology industry.
Jazz Price To Book vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Jazz Pharmaceuticals |
| = | 13.72 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Jazz Pharmaceuticals |
| = | 3.49 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Jazz Price To Book Comparison
Jazz Pharmaceuticals is currently under evaluation in price to book category among its peers.
Jazz Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Jazz Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Jazz Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Jazz Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Jazz Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people.
Jazz Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Jazz Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Jazz Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Jazz Pharmaceuticals' important profitability drivers and their relationship over time.
Use Jazz Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jazz Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jazz Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Jazz Pharmaceuticals Pair Trading
Jazz Pharmaceuticals plc Pair Trading Analysis
The ability to find closely correlated positions to Jazz Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jazz Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jazz Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jazz Pharmaceuticals plc to buy it.
The correlation of Jazz Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jazz Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jazz Pharmaceuticals plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jazz Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Jazz Pharmaceuticals position
In addition to having Jazz Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Jazz Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Jazz Pharmaceuticals plc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Jazz Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.